公开(公告)号：PH12013500858A1

公开(公告)日：2016-01-25

申请号：PH12013500858

申请日：2013-04-29

Applicant: UCB PHARMA SA ,  BIOGEN MA INC

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  YEN-MING HSU ,  LIHE SU ,  TAYLOR FREDERICK R ,  RALPH ADAMS ,  THOMAS BROWN DEREK ,  GEORGE POPPLEWELL ANDREW ,  KIM ROBINSON MARTYN ,  ANTHONY SHOCK ,  LOUISE TYSON KERRY

IPC: A61K39/395 ,  C07K16/28 ,  C12N15/13 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：EA019636B1

公开(公告)日：2014-05-30

申请号：EA200970879

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: Изобретениеотноситсяк связывающимбелкам, включающимантитела, производныеантители фрагментыантител, которыеспецифическисвязываютсяс белком CD154 (CD40L). Такжеданноеизобретениеотноситсяк химерному, гуманизированномуилиполностьючеловеческомуантителу, производномуантителаи фрагментуантитела, которыеспецифическисвязываютсяс эпитопом, скоторымспецифическисвязываетсягуманизированныйфрагмент Fab, содержащийпоследовательностьвариабельнойобластитяжелойцепи SEQ ID NO: 1 исодержащийпоследовательностьвариабельнойобластилегкойцепи SEQ ID NO: 2. CD154-связывающиебелкиподанномуизобретениюмогутпроявлятьпониженнуюэффекторнуюфункциюпосравнениюсовторыманти-CD154-антителом. CD154-связывающиебелкиподанномуизобретениюмогутбытьпригоднымидлядиагностическихи терапевтическихспособов, напримерприлечениии профилактикезаболеваний, втомчислетаковых, которыевключаютнежелательныеиммунныереакции, опосредуемыевзаимодействиями CD154-CD40.

公开(公告)号：SG196697A1

公开(公告)日：2014-02-13

申请号：SG2012055786

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

Abstract: - 126 - Abstract BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODYDERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 ANDUSES THEREOF This invention provides binding proteins, includingantibodies, antibody derivatives and antibody fragments, thatspecifically bind a CD 154 (CD4OL) protein. This invention alsoprovides a chimeric, humanized or fully human antibody, antibodyderivative or antibody fragment that specifically binds to an epitopeto which a humanized Fab fragment comprising a variable heavy chainsequence according to SEQ ID NO: 1 and comprising a variable lightchain sequence according to SEQ ID NO: 2 specifically binds. CD154binding proteins of this invention may elicit reduced effectorfunction relative to a second anti-CD154 antibody. CD154 bindingproteins of this invention are useful in diagnostic and therapeuticmethods, such as in the treatment and prevention of diseasesincluding those that involve undesirable immune responses that aremediated by CD154-CD40 interactions. Fig. 19

公开(公告)号：NZ580245A

公开(公告)日：2012-01-12

申请号：NZ58024508

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: An anti-CD154 antibody that comprises the heavy chain CDR1, CDR2 and CDR3 sequence SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively and the light chain CDR1, CDR2 and CDR3 sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 respectively. Also disclosed are methods of the production of the antibody and uses thereof for treating rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma and multiple sclerosis.